Background. The safety, immunogenicity, and efficacy associated with administration of of aQIV in children 6 months through 5 years of age was investigated. 1 Although enhanced immunogenicity in children was demonstrated for MF59-adjuvanted influenza vaccines after first administration, the impact of repeated vaccination on immunogenicity and safety has not been evaluated.
Methods. A total of 607 subjects who participated in parent study, now aged 12 months through 6 years, were enrolled the subsequent year and received a single dose of study vaccine. Enrolled subjects received the same type of influenza vaccine administered in the parent study (aQIV or nonadjuvanted comparator). Blood samples were taken for immunogenicity assessment prior to the second year vaccination, and 21 and 180 days after vaccination.
Results. At baseline, approximately 12 months after vaccination in the parent study, subjects in the aQIV group had significantly greater geometric mean titer (GMT) values against all four homologous strains compared with subjects in the nonadjuvanted vaccine group. After year 2 vaccination, CBER criteria for seroconversion and hemagglutination inhibition (HI) titer ≥1:40 were met for the aQIV group for all four homologous strains tested at Day 22. At both Day 22 and Day 181, subjects who received aQIV had significantly greater GMT values for HI against all four homologous strains compared with those who received nonadjuvanted vaccine. Increased immune response of aQIV vs. nonadjuvanted vaccine was also observed for the selected heterologous strains tested at baseline, Day 22 and Day 181. In terms of safety, transient and generally mild to moderate reactogenicity was more commonly observed in the aQIV group vs. the nonadjuvanted group, but overall safety profiles were similar and comparable to the parent study.
Conclusion. This first-year revaccination study in young children confirms enhanced immunogenicity and similar safety profile after repeat aQIV vaccination compared with repeat nonadjuvanted influenza vaccination. Veterans Health Administration (VHA) electronic medical records were linked with Centers for Medicare and Medicate Services administrative claims to capture the study outcomes of hospitalizations and baseline characteristics. The inverse probability of treatment weight (IPTW) method was used to adjust for potential confounding due to unmeasured factors associated with IIV3-SD, IIV3-HD, or IIV4 vaccination. The probability was estimated based on patient sociodemographic characteristics, comorbidities, pre-influenza season hospitalizations, prior season influenza vaccination, and use of immunosuppressive medication. Results. Our study population included 782,346 VHA patients vaccinated during the 2014-2015 season. Of these, 10,543 (1%) received IIV4, while 59,536 (8%) received IIV3-HD and 712,267 (91%) received IIV3-SD. 11,626 (1.5%) were female and 588,324 (76%) were non-Hispanic white. Compared with those that received IIV3-SD vaccine, the IPTW-adjusted rVE for IIV3-HD was 7% (95% CI, 9%-21%) against all-cause, 15% (95% CI, 10%-17%) against cardiorespiratory associated, and 13% (95% CI, 8%-17%) against influenza/pneumonia-associated hospitalization. For those that received IIV4, the IPTW-adjusted rVE was 4% (95% CI, 1%-4%), 1% (95% CI, −2%-5%), and 0% (95% CI, −9%-8%), respectively.
Conclusion. IIV3-HD is more effective than, and IIV4 is as effective as, IIV3-SD vaccination in preventing influenza/pneumonia-associated, cardiorespiratory, and allcause hospitalizations. Additional studies that employ methods to control for unmeasured confounding are warranted as the use of IIV4 expands.
Disclosures. All authors: No reported disclosures. Methods. The 2015 Behavioral Risk Factor Surveillance System (BRFSS) telephone survey was used to identify adults in the United States who reported a flu shot in the past year. Based on self-reported date of flu shot, the 2014-2015 flu season was included and divided into early (July-October) vs. late (November-May) vaccination. Settings of vaccination included doctor's office, clinic/hospital, store, and work. Covariates of interest were demographics, having a checkup within previous 1 year, insurance, obesity (BMI ≥ 30), alcohol use, current smoking status, and comorbidities. Comorbidities (hypertension, high cholesterol, stroke, angina, heart attack, skin cancer, other cancer, arthritis, depression, kidney disease, diabetes, asthma, and chronic obstructive pulmonary disease) were categorized as 0, 1-2, or 3+ present. Logistic regression, stratified by age ≥65, identified predictors of early vaccination.
Impact of Influenza Vaccination Setting on Timing of Vaccination in a
Results. A total of 130,615 patients were included. Patients vaccinated in doctor's offices and stores tended to be older and have higher rates of comorbidities compared with those in clinics or at work. In age-stratified analyses, patients 18-64 had higher odds of early vaccination at clinics (odds ratio 1.11, 95% confidence interval 1.02-1.22), stores (OR 1.09, 95% CI 1.002-1.19), and work (OR 1.88, 95% CI 1.71-2.05) compared with doctor's offices. Patients aged ≥65 had higher odds of early vaccination at stores (OR 1.17, 95% CI 1.07-1.27) and work (OR 1.67, 95% CI 1.33-2.09). Patients with certain traits (e.g., males, smokers, and those with children) have lower odds of early vaccination.
Conclusion. Vaccination setting is associated with vaccination timing: nontraditional (store, work) settings increase the odds of receiving a flu shot before the end of October. Age plays a key role in when and where patients receive flu vaccinations. Vaccination programs in nontraditional settings should consider targeting the later flu season to increase participation.
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